Literature DB >> 28382874

Stability and development of psychotic symptoms and the use of antipsychotic medication - long-term follow-up.

D R Gotfredsen1, R S Wils1, C Hjorthøj1, S F Austin1, N Albert1, R G Secher1, A A E Thorup1, O Mors2, M Nordentoft1.   

Abstract

BACKGROUND: Few studies have evaluated the development in the use of antipsychotic medication and psychotic symptoms in patients with first-episode psychosis on a long-term basis. Our objective was to investigate how psychotic symptoms and the use of antipsychotic medication changed over a 10-year period in a cohort of patients with first-episode psychosis.
METHOD: The study is a longitudinal prospective cohort study over 10 years with follow-ups at years 1, 2, 5 and 10. A total of 496 patients with first-episode psychosis were included in a multi-centre study initiated between 1998 and 2000 in Copenhagen and Aarhus, Denmark.
RESULTS: At all follow-ups, a large proportion (20-30%) of patients had remission of psychotic symptoms without use of antipsychotic medication at the time of the follow-up. Patients who were in this group at the 5-year follow-up had an 87% [95% confidence interval (CI) 77-96%] chance of being in the same group at the 10-year follow-up. This stability was also the case for patients who had psychotic symptoms and were treated with antipsychotic medication at year 5, where there was a 67% (95% CI 56-78%) probability of being in this group at the consecutive follow-up.
CONCLUSIONS: A large group of patients with psychotic illness were in remission without the use of antipsychotic medication, peaking at year 10. Overall there was a large degree of stability in disease courses over the 10-year period. These results suggest that the long-term outcome of psychotic illness is heterogeneous and further investigation on a more individualized approach to long-term treatment is needed.

Entities:  

Keywords:  Schizophrenia; long-term outcome.; medication; psychotic illness

Mesh:

Substances:

Year:  2017        PMID: 28382874     DOI: 10.1017/S0033291717000563

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  8 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  The debate regarding maintenance treatment with antipsychotic drugs in schizophrenia.

Authors:  Michael Davidson
Journal:  Dialogues Clin Neurosci       Date:  2018-09       Impact factor: 5.986

3.  Early predictors for late hospitalizations up to 14 years after first episode psychosis.

Authors:  Pontus Strålin; Maria Skott; Johan Cullberg
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2020-12-02       Impact factor: 4.328

4.  Face Your Fears: Virtual reality-based cognitive behavioral therapy (VR-CBT) versus standard CBT for paranoid ideations in patients with schizophrenia spectrum disorders: a randomized clinical trial.

Authors:  U N Jeppesen; A S Due; L Mariegaard; A Pinkham; M Vos; W Veling; M Nordentoft; L B Glenthøj
Journal:  Trials       Date:  2022-08-15       Impact factor: 2.728

5.  The CHALLENGE trial: the effects of a virtual reality-assisted exposure therapy for persistent auditory hallucinations versus supportive counselling in people with psychosis: study protocol for a randomised clinical trial.

Authors:  L C Smith; L Mariegaard; D L Vernal; A G Christensen; N Albert; N Thomas; C Hjorthøj; L B Glenthøj; M Nordentoft
Journal:  Trials       Date:  2022-09-13       Impact factor: 2.728

6.  Tapered discontinuation vs. maintenance therapy of antipsychotic medication in patients with first-episode schizophrenia: Obstacles, findings, and lessons learned in the terminated randomized clinical trial TAILOR.

Authors:  Anne Emilie Stürup; Carsten Hjorthøj; Nikolai Albert; Signe Dolmer; Merete Birk; Bjørn H Ebdrup; Lene Falgaard Eplov; Heidi Jensen; Ditte Lammers Vernal; Helene Speyer; Ole Mors; Merete Nordentoft
Journal:  Front Psychiatry       Date:  2022-07-22       Impact factor: 5.435

7.  Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis.

Authors:  Seoyoung Kim; Sang Ho Shin; Barbara Santangelo; Mattia Veronese; Seung Kwan Kang; Jae Sung Lee; Gi Jeong Cheon; Woojoo Lee; Jun Soo Kwon; Oliver D Howes; Euitae Kim
Journal:  Mol Psychiatry       Date:  2020-09-14       Impact factor: 15.992

8.  TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.

Authors:  Anne Emilie Stürup; Heidi Dorthe Jensen; Signe Dolmer; Merete Birk; Nikolai Albert; Mai Nielsen; Carsten Hjorthøj; Lene Eplov; Bjørn H Ebdrup; Ole Mors; Merete Nordentoft
Journal:  Trials       Date:  2017-09-29       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.